Presentation, response to XXXX therapy, and outcome of @entity8579 -like gastric acid hypersecretors.

@entity1 @entity1066 @entity8579 @entity10042 @entity1624 @entity3137
OBJECTIVE: To evaluate the clinical characteristics, response to treatment and outcome of Zollinger? @entity8579 (ZES)-like gastric acid hypersecretors. METHODS: Over a 20-year period, @entity1 with gastric acid hypersecretion in the absence of ZES were enrolled in an open label prospective trial evaluating the efficacy of @entity10042 . Following baseline evaluations, @entity1 were treated with escalating doses of @entity10042 based on the results of gastric acid analysis. Following stabilization, @entity1 were followed on a 6 monthly basis with interval history, physical examination, endoscopy with gastric biopsies, gastric acid analysis, and laboratory studies. RESULTS: The study group represented 21 @entity1 (median age 47 years, 86% male, 91% Caucasian). Historically, complicated @entity1066 was frequent and symptoms had been present for a median of 10 years before study entry. All @entity1 responded to @entity10042 (median dose 90 mg/day) with excellent control of gastric acid hypersecretion. Mucosal relapse was infrequent and no major complications developed while on therapy. CONCLUSIONS: ZES-like gastric acid hypersecretion presents similarly to the @entity1624 . @entity10042 titrated to gastric acid output is effective in healing @entity3137 and preventing relapse.
